ONCO
Onconetix, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.02
+38.02%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.2x
Market Cap
$4.03M
MomentumView details →
1D Return
+38.02%
YTD Return
−99.09%
RSI (14)
44.2
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.2x
Market Cap
$4.03M
RSI (14)
44.2
MomentumView details →
1D Return
+38.02%
YTD Return
−99.09%
SummaryUpdated Jun 1, 2026
Onconetix, Inc. (NASDAQ:ONCO) is a biotechnology and pharmaceutical company founded in 2018 and headquartered in Cincinnati, Ohio. Originally incorporated as Blue Water Biotech, Inc., the company changed its name to Onconetix in December 2023. The company went public in February 2022 and focuses on developing and commercializing transformational therapies to address various health challenges worldwide. Onconetix operates in the biotechnology sector with a dual focus on commercializing existing FDA-approved treatments and developing innovative vaccine candidates for infectious diseases.
Similar companies
Latest newsMore news →
Onconetix entered into a definitive agreement to acquire Realbotix LLC, a subsidiary of Realbotix Corp.1d agoRealbotix, the acquisition target of Onconetix, secured an agreement with a streaming platform to feature its humanoid robot in an upcoming episode of an Emmy-winning series.29d agoOnconetix, Inc. entered into a committed equity facility agreement allowing it to sell up to $750 million of its common stock over time at prevailing market prices.38d ago